At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 112 enrolled
Drug / intervention
MEDI4736drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
In Brief
A Phase 2 clinical trial evaluating MEDI4736 for Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck. Completed, enrolled 112 participants across 108 sites in 14 countries.
Detailed Summary
Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Canada, Czechia, France, Georgia, Germany, Hungary, Israel, Malaysia, South Korea, Spain, Taiwan, United Kingdom, United States
CollaboratorsPRA Health Sciences
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartOct 2014
Primary CompletionSep 2016
Study CompletionJul 2020
TodayJul 2026
First PostedAug 4, 2014
Enrollment StartOct 23, 2014
Primary CompletionSep 26, 2016
Study CompletionJul 6, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.9 years ago
Interventions
MEDI4736drug
MEDI4736 monotherapy